Erste Erfahrungen mit dem Adrenalinderivat Alupent^®1bei bronchospastischen Zuständen

New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?

“…Timeline for the introduction of adrenergic receptor agonists in asthma treatment [2–16 ]. AR adrenoceptor…”

“…Although highly efficacious, epinephrine caused serious adverse event due to its effect on α and ß -ARs in the cardiovascular system. Isoprenaline [5] and metaproterenol [6] were next AR agonists interacting only with ß-AR but non-selective to their subtypes (Fig. 1) [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16].…”

“…Isoprenaline [5] and metaproterenol [6] were next AR agonists interacting only with ß-AR but non-selective to their subtypes (Fig. 1) [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Their administration was complicated by cardiac adverse events as they did not discriminate between ß1-and ß2-ARs (Fig.…”

“…A series of papers published during that time alarmed the public to the epidemic of sudden deaths due to asthma in England, Wales, Scotland, Ireland, Australia and New Zealand and linked it to an increase in the consumption of isoprenaline (a nonselective β mimetic) [23] and then fenoterol (classified as a selective β2 mimetic Fig. 1 Timeline for the introduction of adrenergic receptor agonists in asthma treatment [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. AR adrenoceptor Kuprys-Lipinska et al Clin Transl Allergy (2020) 10:19 Fig.…”

A Clinical Trial of Alupent, A New Bronchodilator, in General Practice

“…The use of bronchodilators for long‐term oral therapy in order to prevent or abort attacks is, however, much less successful. It is to overcome some of the drawbacks of this form of treatment that the latest member of the series l‐(3,5‐dihydroxy‐phenyl)‐2‐isopropylamino‐ethanol sulphate, (‘Alupent’) has been developed (Engelhardt, Hoefke and Wick 1961 ; Herberg and Sessner 1961).…”